Clinical Trials Logo

Clinical Trial Summary

It is intended for patients who have been admitted to the outpatient or emergency room or are hospitalized For patients who diagnose pulmonary tuberculosis or extrapulmonary tuberculosis using Xpert TB/RIF, additionally, diagnose pulmonary tuberculosis or extrapulmonary tuberculosis using a new diagnostic method, and check the test results. Check whether the tuberculosis bacteria were actually cultured in the sample in the future, and compare the sensitivity and specificity in each test. Validation in animal model In an animal model (rat) with chronic obstructive pulmonary disease that shows similar characteristics to tuberculosis destructive lung, It will be investigated whether the HI method can be validated by separating and concentrating microbiome for various pathogens including Mycobacterium tuberculosis using HI method. Confirm.


Clinical Trial Description

Usefulness of Pulmonary Tuberculosis Diagnosis A comparison of the new diagnostic method with the Xpert TB/RIF test, which is widely used in clinical practice, that can quickly diagnose pulmonary tuberculosis within 1-2 days. ; Considering the sensitivity of the Xpert TB/RIF test as 70% and the sensitivity of the new diagnostic method as 90%, the number of patients with pulmonary tuberculosis required to confirm that the new diagnostic method is useful is estimated as 90 (study power 90%, alpha error = 0.05). And, if 200 patients with suspected pulmonary tuberculosis are registered, it is possible to verify the clinical usefulness compared to Xpert TB/RIF even in 60 AFB smear negative patients. In addition, for the same reason, if 150 additional patients who underwent bronchoscopy were enrolled, it would be possible to compare the diagnosis rate and utility of sputum and bronchoscopy fluid. Waiting for the tuberculosis bacteria culture test for 6 weeks and using the final culture-positive patient as a gold standard for tuberculosis diagnosis -Usefulness of extrapulmonary tuberculosis diagnosis Millet tuberculosis is disseminated tuberculosis through blood, and there are numerous millet-like lesions in the lungs, but in fact, the positive rate of AFB smear is low due to paucibacillary TB. It is planned to prove the usefulness of the new test method in 35 people with millet tuberculosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04988984
Study type Observational
Source Asan Medical Center
Contact
Status Enrolling by invitation
Phase
Start date November 17, 2020
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Completed NCT04545164 - Computer Aided Screening for Tuberculosis in Low Resource Environments N/A
Recruiting NCT05766267 - Short-course Regimens for the Treatment of Pulmonary Tuberculosis Phase 2/Phase 3
Recruiting NCT05756582 - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Recruiting NCT04148053 - Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Recruiting NCT01689831 - Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) Phase 2
Completed NCT05945498 - Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years Phase 1
Not yet recruiting NCT06352970 - Effects of Tuberculosis Infection on Development and Function of the Placenta
Recruiting NCT04575519 - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Phase 2
Recruiting NCT05413551 - Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention Phase 1
Recruiting NCT03941210 - Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
Completed NCT04494516 - Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
Withdrawn NCT03265977 - A Phase II Study of H56:IC31 in Healthy Adolescents Phase 2
Recruiting NCT05069688 - Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Phase 1
Suspended NCT05330884 - BCG Revaccination in Children and Adolescents Phase 3
Recruiting NCT05342064 - Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service N/A
Recruiting NCT05236452 - Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection N/A
Recruiting NCT05443178 - Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy Phase 1
Recruiting NCT05122026 - Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Phase 1/Phase 2
Recruiting NCT06221488 - Testing Health Workers At Risk to Advance Our Understanding of TB Infection